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Scheme 1 The model Dakin–West reaction using TFA as a
catalyst.
Table 1 The effect of amounts of TFA on the yield of the
model reaction shown in Scheme 1.
Reaction TFA (mol%) Time (h) Yield (%)
1 0.00 24 Trace
2 0.15 22 88.6
3 0.30 22 95.2
4 0.45 22 95.5
Scheme 2 Synthesis of b-acetamido ketones catalyzed by TFA.
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Diabetes mellitus (DM) is a chronic disease caused by
inherited or acquired deﬁciency in insulin secretion and/or
insulin resistance. The disease is characterized by increased
blood glucose levels which, in turn, can damage many
physiological systems including blood vessels and nerves1.
Noninsulin-dependent or type 2 diabetes mellitus (T2DM)
accounts for about 95% of all DM and, according to the
World Health Organization (WHO), will likely exceed an
alarming 350 million cases by the year 20302. Owing to this
increasing prevalence, multidisciplinary studies aimed at pre-
venting and treating diabetes is a worldwide research priority.
The generally agreed treatment goal in T2DM is to maintain
near-normal levels of glycemic control in both the fasting and
postprandial states. Although diet and exercise are the ﬁrst steps
toward achieving this goal, oral antidiabetic pharmacotherapy
also plays an important role. Successfully marketed T2DM drugs
may be classiﬁed into insulin secretagogues (meglitinides and
sulfonylureas), insulin sensitizers, aldose reductase inhibitors,
glucose absorption effectors (such as a-glucosidase inhibitors)
and the newly introduced dipeptidyl peptidase 4 (DPP-IV)
inhibitors3. Although these drugs are useful in the treatment of
T2DM, their long-term use may lead to a variety of adverse effects
including hepatotoxicity, weight gain, edema and indigestion.
Thus there remains an urgent need to develop new antidiabetic
agents with higher efﬁcacy and lower toxicity for the long term
treatment of T2DM.
In the course of our previous work, we observed that
b-amino ketones possess remarkable antidiabetic activity4–11.
One issue with the synthesis of such molecules containing
multiple aromatic rings is their bulky space volume. In order
to reduce the space volume of this kind of molecule, we have
designed and synthesized a series of b-acetamidoketones in
which the arylamino group of b-amino ketones is replaced
with an acetamido group.
b-Acetamido ketones are versatile intermediates and useful
building blocks in the synthesis of other important organic
molecules like 1.3-amino alcohols12,13 and antibiotic drugs14,15.
This class of compounds was previously prepared via acylation
of b-amino ketones16, Michael addition of a,b-unsaturated
ketones17,18 or photoisomerization of phthalimides19. However,
the most classical and facile method for the synthesis of
b-acetamido ketones is the Dakin–West reaction. Over recent
years, several catalysts for the Dakin–West reaction have been
developed and now include SnCl2  2H2O20, CeCl3  7H2O21,
ZnO22, SiCl4–ZnCl2
23, heteropoly-acids24, Zr(HSO4)4 and
Mg(HSO4)2
25, PMA/SiO2
26, polyaniline supported acid27,
Mn(bpdo)2Cl2/MCM-41
28, P2O5-HMDS
29, sulfamic acid30
and cellulose sulfuric acid31. Although these catalysts possess
some attractive properties, they also have certain disadvantages
such as requiring a tedious workup, high temperatures, expen-
sive reagents and/or an inert atmosphere as well as producing a
low yield. Therefore, further research and development of new
catalysts is highly desirable.
Triﬂuoroacetic acid (TFA) is not only a useful agent in the
synthesis of ﬂuorine-containing organic compounds and ﬂuor-
opolymers, but is also an important reactant in the acylation
of amino acids32 and the deprotection of peptides33. As a
strongly acidic compound, TFA has been extensively used in
alkylation34 and acylation of aromatic compounds as well as
in the polymerization of oleﬁns. However, the use of TFA as acatalyst in the Dakin–West reaction has not been reported.
Herein, we report the synthesis of a series of b-acetamido
ketones by the TFA-catalyzed Dakin–West reaction and an
evaluation of their antidiabetic activity.2. Results and discussion
In order to establish the efﬁciency of TFA as a catalyst in the
Dakin–West reaction, a model reaction of 4-chloroacetophe-
none (1 mmol) with 4-methylbenzaldehyde (1 mmol) and
acetyl chloride (0.4 mL) was carried out in the presence of
different amounts of TFA in acetonitrile at room temperature
(Scheme 1).
The results (Table 1) show that TFA is necessary for the
reaction to proceed with around 0.30 mol% being the optimal
amount.
To evaluate the scope of the reaction, other aldehydes and
ketones were used (Scheme 2) with the results shown in
Table 2.
Based on the results in Table 2, it is clear that the nature of
the aromatic aldehyde has a major impact on the yield of the
reaction. Thus aromatic aldehydes with electron-withdrawing
groups react more readily than those with electron-donating
groups although reactions 10, 12, 13 and 16 still produce good
yields. In addition, aromatic aldehydes with ortho- or para-
substituents (reactions 4, 5, 9 and 13) react faster than those
with meta-substituents (reactions 3, 7 and 12) with the
exception of nitrobenzaldehyde (reactions 1 and 2). As for
the liquid aldehydes (reactions 7, 8, 9, 11 and 13), reactions
proceeded with the formation of large quantities of solid
products and gave correspondingly high yields (around 90%).
Unexpectedly, the reaction of 4-methoxybenzaldehyde with
4-chloroacetophenone yielded only the corresponding chal-
cone despite stirring the chalcone (1 mmol) in acetonitrile
(3 mL) containing TFA (0.30 mol%) and acetyl chloride
(0.4 mL) for 12 h. Interestingly, aromatic aldehydes with
hydroxy groups yielded corresponding b-acetamido ketones
Table 2 Synthesis of b-acetamido ketones according to Scheme 2.
Reaction X R1 R2 Time (h) m.p. (1C) Yield (%)a
1 4-NO2 4-ClC6H4 H 64 139.5–140.6 83.0
2 3-NO2 4-ClC6H4 H 47 115.4–117.4 87.7
3 3,4-diCl 4-ClC6H4 H 36 221.0–224.0 89.4
4 2,4-diCl 4-ClC6H4 H 24 150.0–151.2 77.5
5 4-Cl 4-ClC6H4 H 16 134.5–136.2 95.5
6 4-Br 4-ClC6H4 H 22 133.6–134.4 83.4
7 3-Cl 4-ClC6H4 H 60 113.0–116.2 90.1
8 3-F 4-ClC6H4 H 28 119.0–121.4 94.0
9 2-Cl 4-ClC6H4 H 28 168.0–170.3 89.0
10 3-CH3O 4-ClC6H4 H 90 107.4–109.7 80.0
11 H 4-ClC6H4 H 22 107.5–109.0 90.0
12 3-CH3 4-ClC6H4 H 110 119.0–122.0 86.3
13 4-CH3 4-ClC6H4 H 22 130.9–133.5 95.2
14 3-CH3O-4-HO 4-ClC6H4 H 36 150.0–152.4 43.5
15 4-HO 4-ClC6H4 H 66 227.9–229.6 53.5
16 3,4,5-triCH3O 4-ClC6H4 H 15 177.2–178.9 85.0
17 H 3-NO2C6H4 H 65 132.1–133.2 96.0
18 2-Cl 4-CH3OC6H4 H 12 155.2–156.7 81.7
19 H CH3 COCH3 24 132.0–133.5 69.0
aIsolated yield.
Table 3 Biological activity of b-acetylamino ketones.
Compound Concentration
(nmol/mL)a
PPAR
activation
(%)
DPP-IV
Inhibition
(%)
1 28.8 2.84 9.53
2 28.8 1.08 4.24
3 26.9 18.45 8.76
4 26.9 1.49 3.79
5 29.7 0.73 8.47
6 26.3 12.21 0.26
7 29.7 0.93 12.71
8 31.0 0.89 7.94
9 29.7 1.53 11.35
10 30.1 0.53 6.30
11 33.1 3.24 4.34
12 31.7 14.17 1.22
13 31.7 16.61 0.48
14 28.8 19.05 4.41
15 31.5 22.86 3.56
16 25.5 14.17 3.61
17 32.0 11.70 –
18 30.1 20.75 –
19 35.5 – –
Positive
controlb
100 73.11
aThe concentration of test compounds is 10.0 mg/mL (the
corresponding nmol/mL is shown).
bPositive controls for PPRE agonist activity and DPP-IV
inhibition activity are pioglitazone (0.78 mg/mL) and KR-62436
(6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylami-
no]ethylamino}nicotinonitrile) (0.78 mg/mL), respectively.
Xing-hua Zhang et al.102(reactions 14 and 15) without further acetylation of the
hydroxy group albeit giving lower yields. However, the
a-substituted enolisable alkyl ketone, 2,4-pentanedione (reac-
tion 19) produced only a moderate yield of the corresponding
b-acetamido ketone. The structure of all products was estab-
lished based on their 1H and 13C NMR spectra.
Given that in previous studies, b-acetamido compounds
displayed no a-glucosidase inhibition activity, we designed the
current series of compounds to target the peroxisome prolif-
erator-activated receptor response element (PPRE) and dipepti-
dyl peptidase 4 (DPP-IV). In evaluating this type of antidiabetic
activity at a concentration of 10.0 mg/mL (Table 3), it was found
that both PPAR agonist activity and DPP-IV inhibition activity
were weak. Nevertheless, the structure–activity relationship
(SAR) for PPAR agonist activity demonstrated that products
with electron-donating groups on the aromatic aldehyde ring
possessed better activity than those with electron-withdrawing
groups in the order: 15 (4-OH)413 (4-CH3)46 (4-Br)41
(4-NO2). Based on these results, we propose that the OH group
in the product of reaction 15 improves water-solubility and
results in stronger binding to the PPAR. The product of reaction
14 is a little less active than that of reaction 15, suggesting that
the additional 3-OCH3 group does not favor the interaction with
PPAR as also seen in the product of reaction 10. Furthermore,
the products of reactions of halogen substituted aromatic
aldehydes (reactions 4, 5, 7, 8 and 9) exhibit some antagonistic
effects.
The presence of different functional groups in the acetophe-
none ring also appears to produce compounds with different
levels of PPAR agonist activity. For example, the product of
reaction 18 (4-CH3O substituent) shows better PPAR agonist
activity than that of reaction 9 (4-Cl substituent).
The bioactivity of a potential drug is dependent on a
number of factors such as the distribution of electron density,
space volume, hydrogen bond density and molecular ﬂexibil-
ity. Through examination of the ChemDraw 3D structures
(Fig. 1), we conclude that the product of reaction 15 haspoorer molecular ﬂexibility than pioglitazone, making it less
able to ﬁt the space structure of PPAR.
Given the limited activity of the target compounds, we
maintain it is essential to synthesize more of these b-acetamido
Figure 1 Three-dimensional structures of the product of reaction
15 and pioglitazone.
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structure–activity relationships. To date, we have synthesized
more than 200 such compounds and evaluation of their
antidiabetic activity is underway.3. Conclusions
We report the use of TFA as an efﬁcient catalyst of the Dakin–
West reaction of aromatic aldehydes, enolizable ketones and
acetonitrile in the presence of acetyl chloride to produce b-
acetamido ketones under mild reaction conditions. We also report
preliminary data on the antidiabetic activity of the b-acetamido
ketones in in vitro assays of PPAR agonist and DPP-IV inhibition
activity. Although the activities were weak, the compounds
represent a valuable starting point in the search for novel
antidiabetic drugs.4. Experimental procedures
4.1. General methods
All solvents and reagents were of chemical or analytical grade.
The progress of reactions was monitored by TLC using
solvent systems of different polarities. Melting points were
measured using an X-6 micro-melting point apparatus and are
uncalibrated. 1H NMR and 13C NMR spectra were recorded
in DMSO-d6 on a Bruker AV-300 spectrometer; chemical
shifts (d) are expressed in ppm downﬁeld from the TMS
internal standard. Coupling constant (J) values are in Hz.
High resolution mass spectra (HRMS) were recorded on a
Bruker Daltonics Data Analysis 3.2, USA.4.2. General procedure for the synthesis of
b-acetamido ketones
To a solution of an enolizable ketone (1.0 mmol), an aldehyde
(1.0 mmol) and acetyl chloride (0.4 mL) in acetonitrile
(2.0 mL), TFA (0.30 mol%) was added dropwise and the
mixture stirred for 0.5 h at 0 1C, and then allowed to warm
to ambient temperature. On completion of the reaction, the
mixture was poured into iced water (20.0 mL) and the pH
adjusted to 7 with saturated NaHCO3, which resulted in
precipitation of the desired b-acetamido ketone. The precipi-
tate was ﬁltered, washed with diethyl ether (1.0 mL) and
recrystallized from a mixture of ethyl acetate and diethyl
ether. Most of the reaction products are known compounds,
which were easily characterized by comparison of their 1H and
13C NMR spectra with those of authentic samples.4.3. DPP-IV inhibition activity
A 200 mL reaction system containing DPP-IV (Sigma), a test com-
pound, and 25 mmol/L HEPES buffer (containing 140 mmol/L
NaCl, 1% BSA and 80 mmol/L MgCl2) was preincubated at
room temperature for 10 min. The reaction was initiated by
the addition of dipeptidyl peptidase Gly–Pro–Gly–Gly, and the
reaction mixture incubated at room temperature for 25–45 min.
The ﬂuorescence intensity (F) at excitation 355 nm and emission
460 nm was then measured. A negative control (no test com-
pound) and a blank control (no enzyme) were run simultaneously.
The test compounds were initially assayed in duplicate at a
concentration of 10 mg/mL. The % inhibition was calculated as
[1(Ftest compoundFblank)/(FnegativeFblank)] 100%. If an inhibi-
tion of more than 50% was observed, the compound was
subsequently consequently tested at six concentrations in duplicate
and the IC50 value calculated using the Xlﬁt software.
4.4. PPAR agonist activity
HepG2 cells were cultured in low glucose DMEM supple-
mented with 100 U/mL streptomycin and penicillin. One day
prior to transfection, the cells were plated in 96-well plates at
1.5 104 cells per well. After reaching 70% conﬂuence,
plasmid pPPRE-Luc with ﬁreﬂy luciferase reporter gene and
the control plasmid phRL-TK with renilla luciferase reporter
gene were transfected into the cells. After 24 h, the medium
was replaced with either fresh medium (negative control) or
fresh medium containing a test compound (10 mg/mL) or
pioglitazone (positive control). Non-transfected cells were
used as blank. After a further 24 h, the expression of
luciferases was measured using the Dual-Luciferase Reporter
Gene Assay Kit (Promega). The percent activation (T%)
were calculated as [(L1SampleL1Blank)/(L1NegativeL1Blank)]/
[(L2SampleL2Blank)/(L2NegativeL2Blank)] 100%, where L1
represents the value for ﬁreﬂy luciferase and L2 the value
for Renilla luciferase.
4.5. Characterization of new products
4.5.1. b-Acetamido-b-(4-bromophenyl)-4-
chloropropiophenone (6)
1H NMR (DMSO-d6, 300 MHz); d 1.77 (s, 3H, COCH3), 3.37
(dd, J¼6.0 and 17.1 Hz, 1H, CH2), 3.56 (dd, J¼8.4 and
17.1 Hz, 1H, CH2), 5.25–5.32 (m, 1H, CHN)), 7.30 (d, J¼8.4
Hz, 2H, Ar–H), 7.49 (d, J¼8.1 Hz, 2H, Ar–H), 7.58 (d,
J¼8.7 Hz, 2H, Ar–H), 7.95 (d, J¼8.7 Hz, 2H, Ar–H), 8.42 (d,
J¼6.0 Hz, 1H, NH). 13C NMR (DMSO-d6, 75 MHz); d 196.4,
168.9, 142.9, 138.6, 135.6, 131.5, 130.4, 129.4, 129.2, 120.3,
48.8, 44.7, 22.9. HRMS calcd. for C17H15BrClNO2Na
401.9865. Found 401.9867.
4.5.2. b-Acetamido-b-(3-ﬂuorophenyl)-4-
chloropropiophenone (8)
1H NMR (DMSO-d6, 300 MHz); d 1.80 (s, 3H, COCH3), 3.40
(dd, J¼6.0 and 17.4 Hz, 1H, CH2), 3.59 (dd, J¼8.7 and
17.4 Hz, 1H, CH2), 5.32–5.39 (m, 1H, CHN), 7.06 (t, J¼8.6
Hz, 1H, Ar–H), 7.20 (d, J¼7.2 Hz, 2H, Ar–H), 7.32–7.39 (m,
1H, Ar–H), 7.59 (d, J¼8.4 Hz, 2H, Ar–H), 7.98 (d, J¼8.7 Hz,
2H, Ar–H), 8.47 (d, J¼7.5 Hz, 1H, NH). 13C NMR (DMSO-d6,
75 MHz); d 196.4, 169.0, 160.9, 146.4, 138.6, 135.6, 130.5,
Xing-hua Zhang et al.104130.4, 129.2, 123.2, 123.1, 113.9, 48.9, 44.8, 22.9. HRMS
calcd. for C17H15ClFNO2Na 342.0669. Found 342.0668.4.5.3. b-Acetamido-b-(3-methoxyphenyl)-4-
chloropropiophenone(10)
1H NMR (DMSO-d6, 300 MHz) d 1.79 (s, 3H, COCH3), 3.36
(dd, J¼5.4 and 16.8 Hz, 1H, CH2), 3.52 (dd, J¼8.4 and
16.8 Hz, 1H, CH2), 3.74 (s, 3H, OCH3), 5.27–5.36 (m, 1H,
CHN), 6.79 (d, J¼8.1 Hz, 2H, Ar–H), 6.93 (s, 1H, Ar–H),
7.22 (t, J¼7.8 Hz, 1H, Ar–H), 7.59 (d, J¼8.7 Hz, 2H, Ar–H),
7.97 (d, J¼8.1 Hz, 2H, Ar–H), 8.41 (d, J¼8.1 Hz, 1H, NH).
13C NMR (DMSO-d6, 75 MHz); d 196.6, 168.9, 159.6, 144.9,
138.5, 135.6, 130.4, 129.7, 129.2, 119.3, 112.9, 112.5, 55.4, 49.4,
45.1, 22.9. HRMS calcd. for C18H18ClNO3Na 354.0869.
Found 354.0867.4.5.4. b-Acetamido-b-(3-methylphenyl)-4-
chloropropiophenone (12)
1H NMR (DMSO-d6, 300 MHz); d 1.79 (s, 3H, COCH3), 2.29
(s, 3H, CH3), 3.34–3.41 (m, 1H, CH2), 3.48–3.52 (m, 1H,
CH2), 5.28–5.33 (m, 1H, CHN), 7.04 (d, J¼8.4 Hz, 1H,
Ar–H), 7.12–7.23 (m, 3H, Ar–H), 7.59 (d, J¼8.7 Hz, 2H,
Ar–H), 7.97 (d, J¼8.7 Hz, 2H, Ar–H), 8.30 (d, J¼8.4 Hz, 1H,
NH). 13C NMR (DMSO-d6, 75 MHz); d 196.7, 168.7, 143.2,
138.5, 137.7, 135.7, 130.4, 129.2, 128.6, 127.9, 127.7, 124.1,
49.4, 45.3, 23.1, 21.5. HRMS calcd. for C18H18ClNO2 Na
338.0922. Found 338.0918.4.5.5. b-Acetamido-b-(3-methoxy-4-hydroxyphenyl)-4-
chloropropiophenone (14)
1H NMR (DMSO-d6, 300 MHz); d 1.77 (s, 3H, COCH3), 3.40
(dd, J¼6.0 and 16.5 Hz, 1H, CH2), 3.48 (dd, J¼8.1 and
16.5 Hz, 1H, CH2), 3.75 (s, 3H, OCH3), 5.22–5.29 (m, 1H,
CHN), 6.68 (d, J¼8.1 Hz, 2H, Ar–H), 6.93 (s, 1H, Ar–H),
7.59 (d, J¼8.4 Hz, 2H, Ar–H), 7.97 (d, J¼8.4 Hz, 2H, Ar–H),
8.32 (d, J¼8.1 Hz, 1H, NH). 13C NMR (DMSO-d6, 75 MHz);
d 197.0, 168.7, 147.8, 145.9, 138.5, 135.8, 134.0, 130.4, 129.2,
119.4, 115.5, 111.6, 56.1, 49.4, 23.0. HRMS calcd. for
C18H18ClNO4 Na 412.0925. Found 412.0917.4.5.6. b-Acetamido-b-(4-hydroxyphenyl)-4-
chloropropiophenone (15)
1H NMR (DMSO-d6, 300 MHz); d 1.75 (s, 3H, COCH3),
3.34–3.36 (m, 1H, CH2), 3.40–3.49 (m, 1H, CH2), 5.20–5.27
(m, 1H, CHN), 6.68 (d, J¼8.4 Hz, 2H, Ar–H), 7.06 (d,
J¼8.7 Hz, 2H, Ar–H), 7.57 (d, J¼8.1 Hz, 2H, Ar–H), 7.94
(d, J¼9.0 Hz, 2H, Ar–H), 8.19 (d, J¼8.1 Hz, 1H, NH), 9.28
(s, 1H, OH). 13C NMR (DMSO-d6, 75 MHz); d 196.9, 168.6,
156.7, 138.5, 135.7, 133.3, 130.4, 129.2, 128.2, 48.9, 45.2, 23.0.
HRMS calcd. for C17H16ClNO3 Na 340.0650. Found 340.0646.Acknowledgments
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